[go: up one dir, main page]

BRPI0908406A2 - Derivados de quinoxalinona como estimulantes da secreção de insulina, métodos para obtenção dos mesmos e uso dos mesmos para tratamento do diabetes - Google Patents

Derivados de quinoxalinona como estimulantes da secreção de insulina, métodos para obtenção dos mesmos e uso dos mesmos para tratamento do diabetes

Info

Publication number
BRPI0908406A2
BRPI0908406A2 BRPI0908406-1A BRPI0908406A BRPI0908406A2 BR PI0908406 A2 BRPI0908406 A2 BR PI0908406A2 BR PI0908406 A BRPI0908406 A BR PI0908406A BR PI0908406 A2 BRPI0908406 A2 BR PI0908406A2
Authority
BR
Brazil
Prior art keywords
stimulants
methods
insulin secretion
treat diabetes
quinoxalinone derivatives
Prior art date
Application number
BRPI0908406-1A
Other languages
English (en)
Inventor
Gerard Botton
Eric Valeur
Micheline Kergoat
Christine Charon
Samer Elbawab
Original Assignee
Merck Patent Ges Mit Beschränkter Haftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Ges Mit Beschränkter Haftung filed Critical Merck Patent Ges Mit Beschränkter Haftung
Publication of BRPI0908406A2 publication Critical patent/BRPI0908406A2/pt
Publication of BRPI0908406B1 publication Critical patent/BRPI0908406B1/pt
Publication of BRPI0908406B8 publication Critical patent/BRPI0908406B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0908406A 2008-03-05 2009-01-15 Derivados de quinoxalinona, processo para a preparação dos mesmos, seu uso e composição farmacêutica BRPI0908406B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08004053 2008-03-05
EP08004053.8 2008-03-05
PCT/EP2009/000209 WO2009109258A1 (en) 2008-03-05 2009-01-15 Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes

Publications (3)

Publication Number Publication Date
BRPI0908406A2 true BRPI0908406A2 (pt) 2015-08-11
BRPI0908406B1 BRPI0908406B1 (pt) 2019-04-09
BRPI0908406B8 BRPI0908406B8 (pt) 2023-02-07

Family

ID=40547943

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908406A BRPI0908406B8 (pt) 2008-03-05 2009-01-15 Derivados de quinoxalinona, processo para a preparação dos mesmos, seu uso e composição farmacêutica

Country Status (18)

Country Link
US (2) US8415352B2 (pt)
EP (1) EP2247580B1 (pt)
JP (1) JP5618837B2 (pt)
KR (1) KR101637387B1 (pt)
CN (1) CN101952258B (pt)
AR (1) AR070797A1 (pt)
AU (1) AU2009221327B2 (pt)
BR (1) BRPI0908406B8 (pt)
CA (1) CA2717718C (pt)
DK (1) DK2247580T3 (pt)
EA (1) EA021904B1 (pt)
ES (1) ES2548583T3 (pt)
HU (1) HUE027811T2 (pt)
IL (1) IL207720A (pt)
MX (1) MX2010009576A (pt)
PT (1) PT2247580E (pt)
WO (1) WO2009109258A1 (pt)
ZA (1) ZA201007059B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9296701B2 (en) 2012-04-24 2016-03-29 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
CA2904641C (en) 2013-03-12 2021-07-20 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
WO2015058067A1 (en) 2013-10-17 2015-04-23 Vertex Pharmaceuticals Incorporated Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors
CN104628661A (zh) * 2015-02-05 2015-05-20 北京理工大学 一类喹喔啉酮衍生物作为醛糖还原酶抑制剂的结构、制备方法及用途
KR102723194B1 (ko) 2015-12-24 2024-10-28 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Cftr 조절제 및 이의 사용 방법
JP6938510B2 (ja) 2015-12-24 2021-09-22 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Cftr制御因子及びこの使用方法
BR112018012934B1 (pt) * 2015-12-24 2023-11-07 The Regents Of The University Of California Reguladores cftr e métodos de uso dos mesmos
CN105769870A (zh) * 2016-04-09 2016-07-20 李曼 一种治疗糖尿病的药物
EP3518931A4 (en) 2016-09-27 2020-05-13 Vertex Pharmaceuticals Incorporated METHOD FOR TREATING CANCER WITH A COMBINATION OF DNA-DAMAGING SUBSTANCES AND DNA-PK INHIBITORS
AU2018321926B2 (en) 2017-08-24 2023-09-21 The Regents Of The University Of California Ocular pharmaceutical compositions
CN109796417A (zh) * 2019-01-14 2019-05-24 北京理工大学 一系列喹喔啉酮衍生物的结构、制备方法及用途
CN109793739A (zh) * 2019-01-14 2019-05-24 北京理工大学 一种喹喔啉酮衍生物的结构、制备方法及用途
CN114957222B (zh) * 2022-05-31 2023-08-15 内蒙古民族大学 化合物及其制备方法和用途
CN114907323B (zh) * 2022-05-31 2023-08-15 内蒙古民族大学 喹喔啉酮类化合物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU410015A1 (pt) * 1971-06-22 1974-01-05
SU616955A1 (ru) * 1977-03-02 2006-12-27 Пермский ордена Трудового Красного Знамени государственный университет им.А.М.Горького 2-(α-бромфенацил)-хиноксалон-3, проявляющий противовоспалительную активность
US4181724A (en) * 1978-09-11 1980-01-01 The Upjohn Company Quinoxalinone compounds useful for expanding the lumina or air passages in mammals
FR2653430B1 (fr) 1989-10-23 1991-12-20 Pf Medicament Nouveaux derives de dihydro-1,2 oxo-2 quinoxalines, leur preparation et leur application en therapeutique.
BR9810456A (pt) 1997-06-27 2001-09-25 Fujisawa Pharmaceutical Co Composto de sulfonamida, método para sua obtenção e seu uso farmacêutico
KR100588247B1 (ko) * 1997-09-01 2006-06-13 교린 세이야꾸 가부시키 가이샤 6,7-비대칭 이치환된 퀴녹살린카복실산 유도체와 이의부가염 및 이들의 제조방법
KR20010042298A (ko) 1998-03-31 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 인자 Xa 및 트롬빈과 같은 세린 프로테아제억제제로서의 퀴녹살리논
DE10343098A1 (de) 2003-09-18 2005-04-14 Bayer Healthcare Ag Tetrahydrochinoxaline und ihre Verwendung
ES2290782T3 (es) * 2004-01-06 2008-02-16 Janssen Pharmaceutica N.V. Derivados de (3-oxo-3,4-dihidro-quinoxalin-2-il-amino)-benzamida y compuestos aferentes como inhibidores de la glucogeno fosforilasa en el tratamiento de la diabetes y de la obesidad.
DE102004023332A1 (de) * 2004-05-12 2006-01-19 Bayer Cropscience Gmbh Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung
WO2007135527A2 (en) * 2006-05-23 2007-11-29 Pfizer Products Inc. Benzimidazolyl compounds

Also Published As

Publication number Publication date
KR101637387B1 (ko) 2016-07-07
BRPI0908406B8 (pt) 2023-02-07
HUE027811T2 (en) 2016-11-28
ES2548583T3 (es) 2015-10-19
ZA201007059B (en) 2011-06-29
MX2010009576A (es) 2010-09-24
EP2247580A1 (en) 2010-11-10
AR070797A1 (es) 2010-05-05
EA201001407A1 (ru) 2011-06-30
IL207720A (en) 2014-12-31
WO2009109258A1 (en) 2009-09-11
EP2247580B1 (en) 2015-07-08
JP2011513343A (ja) 2011-04-28
CA2717718A1 (en) 2009-09-11
CN101952258A (zh) 2011-01-19
DK2247580T3 (en) 2015-10-05
IL207720A0 (en) 2010-12-30
JP5618837B2 (ja) 2014-11-05
PT2247580E (pt) 2015-10-19
BRPI0908406B1 (pt) 2019-04-09
EA021904B1 (ru) 2015-09-30
AU2009221327B2 (en) 2014-03-27
KR20100123899A (ko) 2010-11-25
CA2717718C (en) 2016-05-31
US20130123257A1 (en) 2013-05-16
US20110015194A1 (en) 2011-01-20
US8835634B2 (en) 2014-09-16
US8415352B2 (en) 2013-04-09
AU2009221327A1 (en) 2009-09-11
CN101952258B (zh) 2014-03-19

Similar Documents

Publication Publication Date Title
BRPI0908406A2 (pt) Derivados de quinoxalinona como estimulantes da secreção de insulina, métodos para obtenção dos mesmos e uso dos mesmos para tratamento do diabetes
BRPI0921802A8 (pt) uso de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor,bem como composição e combinação farmacêuticas os compreendendo.
BRPI0919812A2 (pt) combinações de compostos antibacterianos heterocíclicos hirdrogenados com outros compostos antibacterianos e o uso dos mesmos como medicamentos
FR2945534B1 (fr) DERIVES DE CYCLOPENTAL[c]PYRROLE-2-CARBOXYLATES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
BRPI0921389A2 (pt) seringa de um só uso, de inutilização automática
BRPI0920209A2 (pt) conjugados de agonistas de glp-1 e usos dos mesmos
BRPI1013640A2 (pt) composicao farmaceutica, metodos para o tratamento e usos dos mesmos
BR112012000619A2 (pt) seringa pré-preenchida incluindo um absorvedor de oxigênio
BRPI0913726A2 (pt) rapalogs, composições farmacêuticas, métodos de preparo e uso dos mesmos
BRPI0822380A2 (pt) agulha para coleta de sangue com retrocesso
FR2933700B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
ECSP10010494A (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa
FR2953520B1 (fr) Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique
BR112012003842A2 (pt) composição farmacêutica, método de formulação e uso da mesma
BR112015002755A2 (pt) derivado de ácido hialurônico, método de preparação de derivado de ácido hialurônico, método de modificação de derivado de ácido hialurônico e uso de derivados
BRPI0908544A2 (pt) derivados de pirazinona como estimuladores de secreção de insulina, métodos para obtenção dos mesmos, e uso dos mesmos para o tratamento de diabetes
ME03508B (me) Kombinovana terapija za liječenje dijabetesa
BR112012027545A2 (pt) composto de fórmula i, composição farmacêutica, uso da composição farmacêutica, uso de um composto e método de modulação do nível de glicose no sangue em um indivíduo
FR2952934B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
BRPI0915428A2 (pt) derivados de benzoxazinona atuando como agonistas adrenorreceptor beta2 para o tratamento de distúrbios respiratórios
FR2943669B1 (fr) Derives de nicotinamide,leur preparation et leur application en therapeutique
BRPI1010243A2 (pt) derivados de benzotiazinas, preparação dos mesmos e aplicação dos mesmos como fármacos
FR2954943B1 (fr) Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique
BR112012005102A2 (pt) seringa de segurança descártavel com ponta de agulha retrátil
FR2927625B1 (fr) Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/01/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2629 DE 25/05/2021, QUANTO AO ITEM (54) TITULO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2809 DE 05-11-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.